[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355742-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-355742-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","mthfd1l-in-muscle-invasive-bladder-cancer-a-multi-cohort-study-on-prognosis-and-therapeutic-response","MTHFD1L in muscle invasive bladder cancer - a multi-cohort study on prognosis and therapeutic response","","Muscle invasive bladder cancer (MIBC) is an aggressive malignancy with poor outcomes, while platinum-based neoadjuvant chemotherapy and radical cystectomy show limited efficacy and immune checkpoint inhibitors still lack dependable biomarkers. This study evaluates methylenetetrahydrofolate dehydrogenase (NADP-dependent) 1-like (MTHFD1L) as a prognostic marker and predictor of therapeutic response. Using three independent MIBC cohorts and multiple statistical and functional approaches, MTHFD1L expression is linked to unfavorable prognosis and immune-related therapeutic benefit.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mthfd1l-in-muscle-invasive-bladder-cancer-a-multi-cohort-study-on-prognosis-and-therapeutic-response/355742/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mthfd1l-in-muscle-invasive-bladder-cancer-a-multi-cohort-study-on-prognosis-and-therapeutic-response/355742.png","ImageObject",300,407,{"name":42,"@type":43},"Cipher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why is identifying biomarkers important in muscle invasive bladder cancer (MIBC)?","Question",{"text":63,"@type":64},"MIBC is aggressive and current treatments and traditional clinical parameters often fail to accurately predict outcomes. Reliable biomarkers are needed to forecast prognosis and therapeutic response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was MTHFD1L evaluated in the study?",{"text":68,"@type":64},"The researchers analyzed MTHFD1L expression across cancer types, then assessed its prognostic value in three independent MIBC cohorts using Cox regression and Kaplan–Meier analysis. Biological function was explored with enrichment analyses and validation by immunohistochemistry and cell experiments.",{"name":70,"@type":61,"acceptedAnswer":71},"What do the results suggest about MTHFD1L and patient prognosis?",{"text":72,"@type":64},"Across independent MIBC cohorts, higher MTHFD1L expression is associated with significantly worse outcomes and serves as an independent risk factor for poor prognosis.",{"name":74,"@type":61,"acceptedAnswer":75},"Does MTHFD1L relate to immunotherapy response?",{"text":76,"@type":64},"Yes. The study reports that patients with low MTHFD1L expression were more likely to benefit from immune checkpoint inhibitor therapy, supported by expression-linked analyses and experimental findings.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},355742,1790211929,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":113,"preview_page_count":33,"preview_urls":150},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Peng et al. World Journal of Surgical Oncology (2026) 24:228  \n[https://doi.org/10.1186/s12957-026-04346-y](https://doi.org/10.1186/s12957-026-04346-y)  \nWorld Journal of Surgical Oncology  \nRESEARCH Open Access  \nMTHFD1L in muscle invasive bladder  \ncancer: a multi-cohort study on prognosis and therapeutic response  \nSiqiao Peng1†, Yu Liu1†, Peisheng Huang2†, Qinwei Liu3, Le Zhang4, Cheng-Ya Hsu5, Yanru Zeng6,7, Jianming Lu5, Haibo Zhao8* and Chao Cai1*  \nAbstract  \nBackground Bladder cancer is one of the most common malignancies of the urinary tract. Among its subtypes, muscle invasive bladder cancer (MIBC) is particularly aggressive and often associated with poor prognosis. The efficacy of platinum-based neoadjuvant chemotherapy and radical cystectomy remains unsatisfactory. In recent years, immune checkpoint inhibitors have shown promising therapeutic potential in MIBC. However, reliable biomarkers for predicting treatment response are still lacking. Moreover, traditional clinical parameters, such asTNM staging, often fail to accurately assess patient outcomes. Therefore, identifying novel biomarkers is crucial for improving prognosis and optimizing treatment strategies in MIBC.  \nMethods We first analyzed the expression pattern and prognostic significance of methylenetetrahydrofolate dehydrogenase (NADP +dependent) 1-like (MTHFD1L) across multiple cancer types. Subsequently, MIBC patient samples from three independent cohorts (TCGA-BLCA, GSE169455, and GSE48075) were used to evaluate the prognostic value of MTHFD1L through univariate and multivariate Cox regression analyses combined with Kaplan–Meier survival analysis. Gene Set Enrichment Analysis and Gene Set Variation Analysis were performed to explore the biological functions of MTHFD1L. Mutation characteristics and immunotherapy response–related features were further analyzed based on MTHFD1L expression levels. Finally, the results were further verified by immunohistochemistry and cell function experiments.  \nResults MTHFD1L was upregulated in multiple cancer types, and its elevated expression was significantly associated with unfavorable outcomes. In all independent MIBC cohorts, high MTHFD1L expression served as an independent risk factor for poor prognosis. Gene Set Enrichment Analysis indicated that MTHFD1L may promote tumor progression by activating immune-related and proliferative pathways while suppressing metabolic processes. Mutation analysis revealed a higher frequency ofTP53 mutations in the MTHFD1L high-expression group. Moreover, immune response  \n†Siqiao Peng, Yu Liu and Peisheng Huang contributed equally to this work.  \n*Correspondence:  \nHaibo Zhao [haibozhao@gzhmu.edu.cn](haibozhao@gzhmu.edu.cn)[ ](haibozhao@gzhmu.edu.cn)Chao Cai [gycc@gzhmu.edu.cn](gycc@gzhmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-","cbCaivCwWDkALlWa","https://ap.wps.com/l/cbCaivCwWDkALlWa","pdf",3369977,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background","[{\"question\":\"Why is identifying biomarkers important in muscle invasive bladder cancer (MIBC)?\",\"answer\":\"MIBC is aggressive and current treatments and traditional clinical parameters often fail to accurately predict outcomes. Reliable biomarkers are needed to forecast prognosis and therapeutic response.\"},{\"question\":\"How was MTHFD1L evaluated in the study?\",\"answer\":\"The researchers analyzed MTHFD1L expression across cancer types, then assessed its prognostic value in three independent MIBC cohorts using Cox regression and Kaplan–Meier analysis. Biological function was explored with enrichment analyses and validation by immunohistochemistry and cell experiments.\"},{\"question\":\"What do the results suggest about MTHFD1L and patient prognosis?\",\"answer\":\"Across independent MIBC cohorts, higher MTHFD1L expression is associated with significantly worse outcomes and serves as an independent risk factor for poor prognosis.\"},{\"question\":\"Does MTHFD1L relate to immunotherapy response?\",\"answer\":\"Yes. The study reports that patients with low MTHFD1L expression were more likely to benefit from immune checkpoint inhibitor therapy, supported by expression-linked analyses and experimental findings.\"}]","MTHFD1L in muscle invasive bladder cancer - a multi-cohort study on prognosis and therapeutic response | PDF",1790120733,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1dd7c40ccf99a6799fa8055e1340bf2.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9051770cd1ba3be250947004dd026fa.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/608d85e25cb6c25f88089b5c7f2467f1.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5fe3715980747d0853a299bdc5e40b6.webp",980,1306]